Overview

Efficacy Study of ABR-215050 to Treat Prostate Cancer

Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
To investigate ABR-215050 as a possible treatment for prostate cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Active Biotech AB